Home  |  Contact

Cellosaurus A549-CR (CVCL_IP03)

[Text version]
Cell line name A549-CR
Accession CVCL_IP03
Resource Identification Initiative To cite this cell line use: A549-CR (RRID:CVCL_IP03)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Derived from site: In situ; Lung; UBERON=UBERON_0002048.
Sequence variations
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0023 (A-549)
Sex of cell Male
Age at sampling 58Y
Category Cancer cell line
Publications

PubMed=26692948
Zhuo W.-L., Zhang L., Zhu Y., Zhu B., Chen Z.-T.
Fisetin, a dietary bioflavonoid, reverses acquired cisplatin-resistance of lung adenocarcinoma cells through MAPK/survivin/caspase pathway.
Am. J. Transl. Res. 7:2045-2052(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_IP03
Anatomy/cell type resources BTO; BTO:0005816
Encyclopedic resources Wikidata; Q54607013
Entry history
Entry creation03-Mar-2017
Last entry update05-Oct-2023
Version number10